Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Jun 20;8(25):40594-40605.
doi: 10.18632/oncotarget.16505.

Is MPP a good prognostic factor in stage III lung adenocarcinoma with EGFR exon 19 mutation?

Tian Zhang  1 , Jing Wang  1 , Yanjun Su  2 , Xi Chen  1 , Qingna Yan  3 , Qi Li  3 , Leina Sun  3 , Yuwen Wang  1 , Puchun Er  1 , Qingsong Pang  1 , Ping Wang  1
Affiliations

Is MPP a good prognostic factor in stage III lung adenocarcinoma with EGFR exon 19 mutation?

Tian Zhang et al. Oncotarget. .

Abstract

Epidermal growth factor receptor (EGFR) is a transmembrane glycoprotein encoded by a gene located in the short arm of chromosome 7. This study aimed to investigate the clinicopathologic characteristics of classic EGFR exon mutation in Chinese patients with TMN stage III lung adenocarcinoma who received radical surgery. A total of 1,801 lung adenocarcinomas were analyzed for mutations in EGFR; 35% exhibited mutation of classic EGFR exons. Clinical and pathologic characteristics of patients with EGFR exon 19 mutation were compared with those who harbored EGFR exon 21 mutation. Patients with EGFR exon 19 mutation had a higher overall survival (OS, p=0.023) than those harboring EGFR exon 21 mutation. Our results demonstrated that patients with a micropapillary pattern (MPP) pathologic type in EGFR exon 19 mutation had a higher OS (p=0.022), and patients with exon 19 mutation were more sensitive to EGFR-tyrosine kinase inhibitors (p=0.032). The results of the current study can be used in decision-making regarding the treatment of patients with classic EGFR exon mutations.

Keywords: classic EGFR mutations; lung adenocarcinoma; micropapillary pattern; tyrosine kinase inhibitors.

PubMed Disclaimer

Conflict of interest statement

CONFLICTS OF INTEREST

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1. Hematoxylin–eosin staining of MPP-positive specimens
MPP-predominant specimen (A, ×100 magnification; B, ×200 magnification).
Figure 2
Figure 2. Overall survival (OS) and progression-free survival (PFS) of patients with classic EGFR mutations
(A) Kaplan–Meier survival curves for OS analyses between EGFR exon 19 and 21 mutations. (B) Kaplan–Meier survival curves for OS analyses between MPP and non-MPP. (C) Kaplan–Meier survival curves for PFS analyses between TKI and non-TKI as first-line treatment.
Figure 3
Figure 3. Overall survival (OS) and progression-free survival (PFS) of patients with EGFR exon 19 and 21mutations
Kaplan–Meier survival curves for OS between MPP and non-MPP for patients with EGFR exon 19 (A) and EGFR exon 21 (B) mutations. Kaplan–Meier survival curves for PFS between TKI and non-TKI as first-line treatment for patients with EGFR exon 19 (C) and EGFR exon 21 (D) mutations.
Figure 4
Figure 4. Kaplan–Meier survival curves for OS among 4 subgroups, based on EGFR mutation types and pathological types
Kaplan–Meier survival curves for OS among 4 subgroups: EGFR exon 19 mutation and MPP, EGFR exon 19 mutation and non-MPP, EGFR exon 21 mutation and MPP, and EGFR exon 21 mutation and non-MPP.
See this image and copyright information in PMC

References

    1. Parkin DM. Global cancer statistics in the year 2000. The Lancet Oncology. 2001;2:533–543. - PubMed
    1. Spiro SG, Silvestri GA. One hundred years of lung cancer. American journal of respiratory and critical care medicine. 2005;172:523–529. - PubMed
    1. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. The New England journal of medicine. 2004;350:2129–2139. - PubMed
    1. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, Naoki K, Sasaki H, Fujii Y, et al. Science. Vol. 304. New York, NY: 2004. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy; pp. 1497–1500. - PubMed
    1. Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, Ou SH, Dezube BJ, Janne PA, Costa DB, Varella-Garcia M, Kim WH, Lynch TJ, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. The New England journal of medicine. 2010;363:1693–1703. - PMC - PubMed